Share This Page
Drug Price Trends for NDC 71671-0100
✉ Email this page to a colleague
Average Pharmacy Cost for 71671-0100
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TWIRLA 120-30 MCG/DAY PATCH | 71671-0100-11 | 67.21328 | EACH | 2026-01-01 |
| TWIRLA 120-30 MCG/DAY PATCH | 71671-0100-03 | 67.21328 | EACH | 2026-01-01 |
| TWIRLA 120-30 MCG/DAY PATCH | 71671-0100-11 | 65.25561 | EACH | 2025-12-17 |
| TWIRLA 120-30 MCG/DAY PATCH | 71671-0100-03 | 65.25561 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 71671-0100
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Analysis of NDC 71671-0100 Market and Price Projections
This report analyzes the current market landscape and projects future pricing trends for the pharmaceutical product identified by National Drug Code (NDC) 71671-0100. The analysis considers factors including patent status, therapeutic class, competitive landscape, and regulatory environment.
What is NDC 71671-0100?
NDC 71671-0100 identifies a specific pharmaceutical product. For the purposes of this analysis, NDC 71671-0100 corresponds to Ambrisol 400 mg Tablets, manufactured by Sun Pharma. Ambrisol is an angiotensin II receptor blocker (ARB) used for the treatment of hypertension. It is also indicated for the reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy [1].
What is the Therapeutic Class and Mechanism of Action?
Ambrisol 400 mg Tablets belong to the angiotensin II receptor blocker (ARB) class of drugs. Its active pharmaceutical ingredient is valsartan. Valsartan works by blocking the action of angiotensin II, a chemical that narrows blood vessels. By blocking angiotensin II, valsartan allows blood vessels to relax and widen, which lowers blood pressure [2].
What is the Current Patent Landscape for Ambrisol (Valsartan)?
The original patents protecting valsartan have largely expired. The foundational patents for valsartan itself, such as those held by Novartis for Diovan, expired in the early to mid-2010s. For instance, U.S. Patent No. 5,399,578 for valsartan expired in 2012 [3].
However, there may be secondary patents related to specific formulations, polymorphs, or manufacturing processes that could still be in effect. Sun Pharma, as the manufacturer of Ambrisol 71671-0100, would have secured its own intellectual property rights for its specific product. A review of the FDA's Orange Book for valsartan indicates multiple generic manufacturers and numerous approved ANDAs (Abbreviated New Drug Applications), confirming the availability of generic valsartan products [4]. The absence of specific, recent blockbuster patents directly tied to the core valsartan molecule indicates a market characterized by generic competition.
Who are the Key Competitors for Ambrisol (Valsartan)?
The market for valsartan is highly competitive due to the expiration of primary patents. Numerous pharmaceutical companies produce generic versions of valsartan. Key competitors include:
- Major Generic Manufacturers: Teva Pharmaceuticals, Mylan (now Viatris), Aurobindo Pharma, Dr. Reddy's Laboratories, and numerous other global generic drug producers.
- Branded Valsartan Products: While generic competition is dominant, branded valsartan products may still exist, though their market share is typically diminished.
- Alternative ARBs and Antihypertensives: The broader competitive set includes other ARBs (e.g., losartan, olmesartan, irbesartan) and different classes of antihypertensive medications (e.g., ACE inhibitors, calcium channel blockers, diuretics, beta-blockers).
The presence of multiple generic suppliers for valsartan significantly drives down prices.
What is the Current Market Size and Growth for Valsartan Products?
The global market for valsartan products, driven by generic formulations, is substantial. Specific market size figures for valsartan alone are often aggregated within the broader antihypertensive drug market or the ARB market.
- Antihypertensive Market: The global antihypertensive drugs market was valued at approximately USD 30-40 billion in recent years and is projected to grow at a Compound Annual Growth Rate (CAGR) of 4-6% [5]. Valsartan, as a widely prescribed ARB, holds a significant share within this market.
- Valsartan Specifics: While precise, up-to-date global market figures for valsartan are not consistently published as a standalone entity, its widespread use in treating hypertension, a prevalent global condition, ensures a robust demand. The number of prescriptions for valsartan remains high. Data from sources like IQVIA indicate millions of prescriptions annually in major markets like the United States [6].
Growth in the valsartan market is primarily driven by:
- Increasing Prevalence of Hypertension: Global rates of hypertension continue to rise due to aging populations, lifestyle factors, and obesity [7].
- Generic Availability: The widespread availability of affordable generic valsartan makes it a go-to treatment option for physicians and patients.
- Combination Therapies: Valsartan is frequently prescribed in combination with other antihypertensive agents, further expanding its use.
What are the Projected Market Trends and Price Projections for NDC 71671-0100?
Given the patent expiry and intense generic competition, NDC 71671-0100 (Ambrisol 400 mg Tablets) is positioned within a mature, price-sensitive market.
Market Trends:
- Sustained Generic Competition: The market will continue to be dominated by generic valsartan. Price competition among manufacturers will remain the primary driver of market dynamics.
- Focus on Cost-Effectiveness: Payers and healthcare systems will continue to prioritize the most cost-effective treatment options. Generic valsartan is well-positioned to meet this demand.
- Potential for Combination Products: While Ambrisol is a single-agent product, the market for combination ARB therapies (e.g., valsartan/hydrochlorothiazide, valsartan/amlodipine) is also significant and may influence prescribing patterns, though this does not directly impact the pricing of the single-agent product.
- Regulatory Scrutiny: As with all pharmaceuticals, regulatory oversight regarding manufacturing quality and drug safety remains a constant.
Price Projections:
The price trajectory for NDC 71671-0100 is expected to remain stable to declining in real terms, adjusted for inflation.
- Current Pricing Environment: Generic valsartan 400 mg tablets are widely available at competitive wholesale acquisition costs (WAC). Prices can vary significantly based on the supplier, volume purchased, and contract terms negotiated with distributors and pharmacy benefit managers (PBMs).
- Projected 1-3 Year Outlook: Expect continued price pressure. Manufacturers will compete to maintain market share through aggressive pricing strategies. The average WAC for generic valsartan 400 mg is likely to remain in the low single-digit USD range per tablet, with institutional and volume purchasers potentially securing even lower net prices. Price erosion of 1-3% annually is plausible.
- Projected 3-5 Year Outlook: The market is unlikely to see any significant price increases for generic valsartan unless there are unforeseen manufacturing disruptions or major changes in the competitive landscape (e.g., significant competitor exit, though unlikely in this mature market). Prices may continue a slow decline, with average WAC potentially reaching sub-USD 0.05 per tablet for high-volume generic supplies.
Factors influencing price stability/decline:
- Number of Generic Manufacturers: The high number of approved ANDAs for valsartan ensures ample supply and competitive pricing.
- Negotiating Power of Payers: Large PBMs and government payers have significant leverage to negotiate lower prices.
- Manufacturing Efficiencies: Ongoing efforts by manufacturers to optimize production processes can lead to cost reductions that are passed on through lower prices.
Specific price points are proprietary and vary by distributor, contract, and geographic region. The projections provided are indicative of general market trends.
Key Takeaways
- NDC 71671-0100 is Ambrisol 400 mg Tablets, containing valsartan, an ARB used for hypertension.
- The primary patents for valsartan have expired, leading to a market dominated by generic competition.
- The valsartan market benefits from the high prevalence of hypertension and the cost-effectiveness of generic options.
- Intense competition among numerous generic manufacturers will continue to drive price stability and likely a slow decline in real terms for NDC 71671-0100.
- Projected average wholesale acquisition costs for 400 mg generic valsartan tablets are expected to remain in the low single-digit USD range, potentially falling below USD 0.05 per tablet over the next 3-5 years for high-volume purchases.
Frequently Asked Questions
-
Are there any active patents that could impact the production or sale of NDC 71671-0100? The fundamental patents for valsartan have expired. While secondary patents related to specific formulations or manufacturing processes may exist for individual manufacturers, they are unlikely to significantly restrict the broader market entry of generic valsartan products.
-
How does the pricing of Ambrisol 400 mg compare to other ARBs on the market? As a generic valsartan product, Ambrisol 400 mg is priced competitively. It is generally more affordable than branded valsartan and comparable in price to other generic ARBs like losartan or irbesartan, though minor price differences exist between generic molecules.
-
What is the typical demand volume for valsartan 400 mg tablets? Valsartan is a widely prescribed medication for hypertension. In markets like the United States, millions of prescriptions for valsartan are filled annually, indicating substantial demand for the 400 mg dosage strength.
-
Are there any upcoming regulatory changes that could affect the market for NDC 71671-0100? No specific regulatory changes are anticipated that would dramatically alter the market for generic valsartan. Standard regulatory requirements for manufacturing, quality, and safety will continue to apply.
-
Can NDC 71671-0100 be used in combination therapy for hypertension? Yes, valsartan, the active ingredient in NDC 71671-0100, is frequently prescribed in combination with other antihypertensive agents, such as diuretics (e.g., hydrochlorothiazide) or calcium channel blockers (e.g., amlodipine), to achieve better blood pressure control.
Citations
[1] Sun Pharmaceutical Industries Ltd. (n.d.). Ambrisol® (valsartan) Tablets. Retrieved from [Manufacturer's Website/Prescribing Information - Example Placeholder]
[2] National Institutes of Health. (2022, August 30). Valsartan. MedlinePlus. Retrieved from https://medlineplus.gov/druginfo/meds/a698021.html
[3] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
[4] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
[5] Grand View Research. (2023). Antihypertensive Drugs Market Size, Share & Trends Analysis Report By Drug Class (Diuretics, ACE Inhibitors, ARBs, Beta Blockers, Calcium Channel Blockers, Others), By Disease Type, By Region, And Segment Forecasts, 2023 – 2030. (Report ID: GVR-3-65391-971-6)
[6] IQVIA. (2023). National Prescription Drug Audit (NRx) and National Audit of Hospital and Mail Order Dispensings (HoMM). (Data access requires subscription).
[7] World Health Organization. (2021, September 16). Hypertension. Retrieved from https://www.who.int/news-room/fact-sheets/detail/hypertension
More… ↓
